Norway· NO-ID_B07A611F-6D76-4C18-B1E4-CC7DF550B98E
Imlygic
A talimogene laherparepvec product containing talimogene laherparepvec, registered in Norway by Amgen Europe B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Talimogene laherparepvec is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL02 (talimogene laherparepvec), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Talimogene laherparepvec · ATC L01XL02
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Talimogene Laherparepvec
- Manufacturer
- Amgen Europe B.V.
- Country
- Norway (NO)
- ATC code
- L01XL02
- ATC class
- Talimogene laherparepvec
- Defined daily dose
- 0.14 DE, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_B07A611F-6D76-4C18-B1E4-CC7DF550B98E
- no_varenummer0508261NOK 29392.6
- gtin8715131025663
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
289 interactions on record for talimogene laherparepvec.
Graded by severity as the source publishes them — 284 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Talimogene laherparepvec · interactions on record
289 records
- 284 severe
- 5 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Talimogene laherparepvec in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomImlygic 100million plaque forming units/1ml solution for injection vialsAmgen Ltd
- SwitzerlandImlygic
- CzechiaIMLYGICAmgen Europe B.V., Breda
- SpainIMLYGIC 1x10e6 UFP/ml solucion inyectableAmgen Europe B.V.
- FinlandImlygicAmgen Europe B.V.
- IrelandImlygic 10e6 plaque forming units (PFU)/mL solution for injectionAmgen Europe B.V.
- IcelandImlygicAmgen Europe B.V.*
- NetherlandsImlygic 106 plaquevormende eenheden (PFU)/ml oplossing voor injectieAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Iceland · Imlygic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8dbcbaaf-a2a8-4095-afa1-ce00a721958e GET /v1/drugs/8dbcbaaf-a2a8-4095-afa1-ce00a721958e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Talimogenlaherparepvek",
"merkevare_id": "ID_B07A611F-6D76-4C18-B1E4-CC7DF550B98E",
"name_form_strength": "Imlygic inj, oppl 1000000 PFU/ml",
"prescription_group": "C"
}See everything about talimogene laherparepvec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.